# ZYPITAMAG® (pitavastatin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pitavastatin

> The FDA approved ZYPITAMAG® (pitavastatin), sponsored by MEDICURE INC (MCUJF), on July 14, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZYPITAMAG® (pitavastatin) |
| Codes |  |
| Sponsor | MEDICURE INC (MCUJF) https://sec-api.dev/companies/mcujf/catalysts |
| Indications | disseminated superficial actinic porokeratosis planned for second half of 2026, disseminated superficial actinic porokeratosis planned for the second half of 2026 |
| Modality |  |
| FDA designations | fast track |

## Timeline

### July 14, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208379 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20170714, review_priority STANDARD; sponsor_name MEDICURE; product ZYPITAMAG (PITAVASTATIN MAGNESIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208379%22

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: disseminated superficial actinic porokeratosis planned for second half of 2026.
- First seen 2025-11-05, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331556): "Initiation of Phase 2 trial of QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210605): "Initiation of Phase 2 trial of QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-133332): "Initiation of Phase 2 trial of QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for second half of 2026" https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-106591): "Filed intellectual property Initiation of Proposed Phase 2 study anticipated in 2H 2026" https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/tm2530285d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pitavastatin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZYPITAMAG® (pitavastatin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pitavastatin

```bibtex
@misc{secapidev_pdufa_pitavastatin_20261116,
  title        = {ZYPITAMAG® (pitavastatin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pitavastatin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pitavastatin_20261116","title":"ZYPITAMAG® (pitavastatin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pitavastatin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
